Company: JUNS
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023603
Chunk: 17

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 8
Chunk 17
---
 the Company ownership of any regulatory approvals as well as the sole and exclusive worldwide right to develop,
manufacture and commercialize all products, including JOTROL. Aquanova has been granted an exclusive license to conduct formulation
development and manufacturing.

The
License Agreement defines various fees due to Aquanova for product and formulation development and licensing of the products. The Company
is obligated to pay Aquanova an annual license fee of $75,000 in the year and each year subsequent thereto the acceptance of the product
formulation by both parties. Such annual license fee requirement terminates in the year in which marketing authorization approval (“MMA”)
is obtained in a single territory, which as of September 30, 2024 has not been received. Upon receipt of MMA in each territory (e.g.,
United States, European Union, China, Japan), the Company will be obligated to pay $200,000 to Aquanova per territory in which an MMA
approval obtained, up to a maximum of $600,000, in aggregate. In addition, upon commercialization the Company will be obligated to pay
Aquanova a royalty equal to 5% of net sales, as defined, in each territory until the later of (i) ten years after the first commercial
sale; (ii) the first date there is no valid claim within the Aquanova patent rights; or (iii) the MMA expiration date in each territory.
As of September 30, 2025 and December 31, 2024, has accrued $56,250 and $75,000, respectively, license fees which are included in accounts
payable and accrued expenses on the accompanying condensed consolidated balance sheets

Finally,
pursuant to the terms of the License Agreement, upon mutual agreement, the Company may pay a one-time royalty of $3,000,000 within 180
days of United States marketing approval 1.25% royalties on net sales in the United States in lieu of the terms as set forth above.

Murdoch
Children’s Research Institute

In
2015, the Company entered into a Global Development and License Agreement (“License Agreement II”) with Murdoch Children’s
Research Institute (“MCRI”), an Australian Institute at the Royal Children’s Hospital in Australia, with the know-how
in the process of using pharmaceutical grade Resveratrol for the treatment of Friedreich’s ataxia. License Agreement II provides
for joint development for a delivery system, clinical trials for the treatment of Friedreich’s ataxia, and worldwide commercial